Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea

Recruiting now

Conditions studied: Cancer of Breast, Trastuzumab Emtansine, Trastuzumab Deruxtecan

In brief

Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea

Key facts

Study ID

NCT06928818

Run by

Seoul National University Hospital

People needed

100

Starts

2025-02-26

Expected to finish

2029-09-30

Last updated by the study team

2026-04-23

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HER2-positive, advanced (unresectable locally advanced or metastatic) breast cancer
• Prior treatment with trastuzumab deruxtecan(T-DXd) in the advanced setting
• Intention to treat with Trastuzumab Emtansine (T-DM1) as first therapy upon T-DXd progression

You may not qualify if…

• Any systemic treatment, other than T-DM1, for breast cancer after trastuzumab deruxtecan (As an exception, patients treated with endocrine agents, not in combination with cytotoxics or antibody-drug conjugates, will be permitted in the study)
• Has been previously treated with T-DM1 for advanced breast cancer
• Has been previously treated with 4 or more lines of therapy for advanced breast cancer
• Half (50%) or more patients will be those who were treated with second-line trastuzumab deruxtecan (i.e. patients at the later line will be capped).

Where it is running

• Seoul National University Hospital — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.